Compare iShares MSCI Indonesia ETF (EIDO) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI Indonesia ETF trades at $11.83 (market cap $398.15M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 25.7× iShares MSCI Indonesia ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EIDO | GMED | |
|---|---|---|
Market Cap | $398.15M | $10.25B |
Volume | 3,087,911 | 1,059,528 |
52-Week High | $19.22 | $96.82 |
52-Week Low | $10.80 | $58.33 |
Typical Hold Time | 76 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.71, up 0.34% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces selling pressure. Recent news highlights declining trading volume and questions about Indonesia's commodity benefits. Financial ratios remain undisclosed in current data.
Outlook remains cautious due to technical downtrend and sector concentration risks. The 44% financials weighting and modest EPS growth limit upside potential. Seasonal patterns may offer brief relief, but structural challenges persist for sustained appreciation.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
